Menu

Revance EDGE Partner Program Terms and Conditions

Updated December 1, 2024

EDGE Partner Program Rules and Eligibility

The Revance EDGE Partner Program (the “Program” or “EDGE”), is a program owned and operated by Revance Therapeutics, Inc. (“Revance,” “we,” “us,” or “our”) and is available and provided to you (“account,” “you” or “user”) under the terms and conditions set forth herein, including any amendments thereto and with any additional terms and conditions, rules or policies that may be applicable to particular offerings made in connection with the Program (collectively, the “Terms and Conditions”) and all applicable laws and regulations.

The Program applies to your eligible purchases of Revance products DAXXIFY® and/or RHA® Collection of dermal fillers (collectively, the “Products”). Eligibility for the Program is determined by the dollar amount of Product purchases based on ESSENTIAL tier pricing, less any returns. The timing and amount of purchases are determined based on the date of Product order. Only Products directly invoiced by Revance and purchased through its authorized distributor(s) will count toward the Program, including Program benefits.

Subject to approval by Revance, multiple accounts may combine Product purchases for Program qualification purposes if the accounts share a common tax ID number and legitimately conduct business as a single entity.

Your failure to follow the Program’s Terms and Conditions or rules, whether set forth below or in supplemental notices posted at various points in the Program, may result in termination of your access and participation in the Program and all benefits you have accrued in the Program, without notice, in addition to Revance’s other remedies.

This Program supersedes and replaces all other healthcare professional reward programs applicable to the Products. These Terms and Conditions supersede all previous loyalty program rules and/or terms and conditions applicable to the Products.

These Terms and Conditions may be modified by Revance from time to time, without advanced notice. Any such changes shall be reflected in an updated version of the Terms and Conditions posted at https://revanceaesthetics.com/edge-terms.

BY PARTICIPATING IN THE PROGRAM, YOU ACCEPT, WITHOUT LIMITATION OR QUALIFICATION, ALL OF THE TERMS AND CONDITIONS. You agree that Revance will not be liable to you or any third party for any modification or discontinuance of the Program, in whole or in part.

EDGE Benefits

EDGE provides certain benefits, as described below, based on Product purchases. EDGE consists of five (5) levels based on the semi-annual spend for Products, as described in the table below. You must purchase the minimum dollar amount of Products in each semi-annual period, as set forth in the chart below, in order to become eligible and maintain your eligibility for EDGE benefits.

Initial and Special Tier Qualification for 2025: Upon the launch of the Revance EDGE program on April 1, 2025, initial tier qualification will be determined based on the cumulative purchases of Revance products during Q4 2024 and Q1 2025. This initial evaluation will set the tier for each account. Additionally, to facilitate tier progression throughout 2025, Revance EDGE will implement a 'double counting' mechanism. Specifically, the spend from Q1 2025 will be counted twice for tier qualification purposes. This means that your tier status as of July 1, 2025, will be based on the combined spend from Q1 2025 and Q2 2025.

From July 1 2025, your level, corresponding savings discount, and other benefits for a semi-annual period will be determined based on the cumulative qualifying dollar amount purchases of Products based on ESSENTIAL tier pricing that you made during the previous semi-annual period. The semi-annual periods shall be January 1 – June 30, and July 1 – December 31. The qualifying Product purchase amounts and corresponding benefits are described in the chart below.

Your level and corresponding savings discount are eligible for an instant upgrade at the time of order if the qualifying order dollar amount, combined with previous qualifying purchases in that semi-annual period, reaches the dollar amount threshold for that level. The highest level achieved, and the associated savings discount will be applied for the rest of that semi-annual period and the following semi-annual period.

Beginning April 1, 2025, qualifying purchases of Products are eligible for benefits based on your Program level, as provided in the table below.

MOQs of 10 vials for DAXXIFY and 5 boxes for RHA Collection by Teoxane still apply, no matter the tier.

The benefits described above are awarded and exercisable in the semi-annual period following the period in which they are earned based upon cumulative qualifying purchases of Products in the prior period, and are valid for a period of six (6) months after the end of the qualifying semi-annual period.

Revance may, from time to time, add additional benefits to EDGE on a temporary or permanent basis.

Program Status

Your Program status and ordering information can be accessed through the Revance EDGE website, an assigned sales representative, if applicable, and via email or phone using the contact information on https://revance.com.

Program Limitations

This Program is limited to licensed U.S. healthcare providers who purchase Revance products from Revance through its authorized distributor(s). You may not resell the product to other healthcare professionals without the prior, written consent of Revance. Any or all rewards, savings, discounts, rebates, or benefits under this Program may not be transferred to any other party, and each reward, savings, discount, rebate, or benefit under this Program shall be considered void if obtained fraudulently or where prohibited or restricted by law. The Program is void where prohibited or restricted by law. Revance reserves the right to limit purchase quantities.

Benefits described in the program are not redeemable for cash, transferable, or assignable for any reason and cannot be sold, traded, bartered, auctioned through an online auction site, or otherwise; any such Program benefits may be confiscated by Revance and/or canceled.

Reservation of Rights

The Program and its benefits are offered at Revance’s discretion, and Revance has the right to modify or discontinue, temporarily or permanently, the Program, in whole or in part, for any reason, at our sole discretion. You agree that Revance will not be liable to you or any third party for any modification or discontinuance of the Program.

Use of Your Information and Personal Information

The information you provide in connection with the Program will be used by Revance and its affiliates, agents, contractors and vendors for the administration of the Program and to provide you information about the Program and Products. Revance may also use any information you provide for our internal purposes, including to better understand your needs and how to improve our processes, products and services, and to send you information about Revance and its products and services, as well as special offers or other opportunities from Revance or its business partners that may be of interest.

Revance understands that protecting your personal information (such as name, address, telephone number, email address, and other information) is very important. Revance does not share any personal information you provide us with third parties for their own marketing use.

By participating in the Program, you agree to Revance sharing your information, including your personal information, with third parties including Revance’s affiliates, contractors, agents and vendors. Revance may also combine your personal information with information from third parties to better match special offers with your interests. If you do not wish Revance to use or share your information or send information to you about the Program, Revance its products and services, and special offers, you should not participate in the Program. By participating in the Program, you agree we may collect, share and use any information about you that you provide us in accordance with these Terms and Conditions and our Privacy Policy which can be found at https://www.revance.com/privacy-policy/.

Limitation of Liability; Release

Revance and its affiliates and their respective representatives, agents, directors, officers, shareholders, and employees (“Revance Entities”) are not responsible for and shall not be liable for: (i) telephone, electronic, hardware or software program, network, Internet, computer or other malfunctions, failures, or difficulties of any kind, whether human or technical; (ii) failed, incomplete, garbled, or delayed computer transmissions; (iii) any condition caused by events beyond our control; (iv) any injuries, losses, or damages of any kind arising in connection with or as a result of a benefit or acceptance, delivery or failure to timely deliver, possession, or use of a benefit, or from participation in the Program; or (v) any printing or typographical errors in any materials associated with the Program. Further, in no event shall the Revance Entities be liable for any damages of any kind or nature, including but not limited to, direct, indirect, incidental, consequential, exemplary, special (including loss of revenue or profit), punitive, or other damages arising from or in connection with the existence or use of the Program, or any such dispute, regardless of whether any of the Revance Entities have been advised as to the possibility of such damages. You acknowledge that you are solely and exclusively responsible for accurately reporting prices, income, taxes or other information to government agencies and other entities, as applicable.

Proprietary Rights

All Revance and Product names, logos, and service marks in these Terms and Conditions are registered or unregistered trademarks owned by or licensed to Revance or our affiliates, unless otherwise identified as being owned by another entity. Nothing contained herein shall be construed as conferring by implication, estoppel, or otherwise any license or right, either express or implied, under any patent or Trademark of Revance or any third party. No use of any trademark may be made without our prior written authorization.

Governing Law & Disputes

These Terms and Conditions shall be governed by and construed in accordance with the laws of the State of California without regard to choice of law principles. All applicable federal, state, and local laws and regulations apply. The invalidity or unenforceability of any provisions of these Terms and Conditions shall not affect the validity or enforceability of any other provision. In the event that any provision of these Terms and Conditions is found to be invalid or unenforceable, these Terms and Conditions shall be construed in accordance with their terms as if the invalid or unenforceable provision was not contained therein.

For full Prescribing Information including BOXED WARNING for DAXXIFY® visit https://hcp.daxxify.com/. For Directions for Use for the RHA® Collection by Teoxane , visit https://rha.revanceaesthetics.com/.

©2025 Revance Therapeutics, Inc. All rights reserved. DAXXIFY® is a registered trademark of Revance Therapeutics, Inc. RHA ® is a registered trademark of TEOXANE SA, manufactured in Switzerland. RHA Redensity is a trademark of Teoxane SA. The RHA® Collection is exclusively distributed by Revance Aesthetics™. All other trademarks are the property of their respective owners.

INDICATION

DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than glabellar lines.

IMPORTANT SAFETY INFORMATION

Contraindications
DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions
The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Drug Interactions
Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations
DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

DAXI-001720.2

PLEASE SEE FULL DIRECTIONS FOR USE

RHA® Collection of Fillers, by Teoxane

Indications:

The RHA® Collection of resilient hyaluronic acid (HA) fillers includes RHA® Redensity™, RHA® 2, RHA® 3 and RHA® 4.

RHA® Redensity™ is indicated for injection into the dermis and superficial dermis of the face, for the correction of moderate to severe dynamic perioral rhytids in adults 22 or older. RHA® 2 is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds in adults 22 or older. RHA® 3 is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds and is also indicated for injection into the vermillion body, vermillion border and oral commissure to achieve lip augmentation and lip fullness in adults 22 or older. RHA® 4 is indicated for injection in the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds in adults 22 or older.

IMPORTANT SAFETY INFORMATION

Contraindications:

Do not use in patients who have severe allergies, marked by a history of anaphylaxis or multiple severe allergies, or in patients with a history of allergies to gram-positive bacterial proteins or local anesthetics of the amide type, such as lidocaine.

Do not use in patients with bleeding disorders.

Warnings:

Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, inject the product slowly and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures.

Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur.

Product use at specific sites in which an active inflammatory process or infection is present should be deferred until the underlying process has been controlled.

Precautions:

These products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy.

Discuss the potential risks of soft-tissue injections with your patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications.

The safety and effectiveness for the treatment of anatomic regions other than the labeled indications have not been established in controlled U.S. clinical studies. As with all transcutaneous procedures, dermal filler implantation carries a risk of infection. Standard precautions associated with injectable materials should be followed.

The safety for use in sites in the presence of other implants, during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied.

Use with caution in patients on immunosuppressive therapy.

Patients who are using products that can prolong bleeding (such as thrombolytics, anticoagulants, or inhibitors of platelet aggregation) may experience increased bruising or bleeding at treatment sites.

Patients with a history of herpetic eruptions may experience reactivation of the herpes. There is a possible risk of inflammation at the implant site if laser treatments or a chemical peel are performed after treatment.

Use as supplied. Modification or use of the product outside the Directions for Use may adversely impact the sterility, safety, homogeneity, or performance of the product.

For single patient use. Do not reuse a syringe between two treatments and/or between two patients. Do not resterilize.

Adverse Events:

The most commonly reported side effects were firmness, redness, tenderness, swelling, lumps/bumps, bruising, discoloration, pain and itching. Most of these events were mild or moderate and resolved within 14 days.

Delayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers. Cases of delayed-onset inflammation have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own.

To report an adverse reaction with any RHA® product, please call Revance at (877) 373-8669.

RHA® is a registered trademark of TEOXANE SA, manufactured in Switzerland. The RHA® Collection is exclusively distributed by Revance Aesthetics™.

Available by Prescription only
RHA-P-002436.3

REFERENCES

1. DAXXIFY®. Prescribing Information. Revance Therapeutics, Inc; 2023
2. Fabi SG, Cohen JL, Green LJ, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study. Dermatol Surg. 2020;47(1):48-54.
3. BOTOX® Cosmetic. Prescribing Information. Allergan Inc; 2023.
4. Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45-58.
5. XEOMIN®. Prescribing Information. Merz Pharmaceuticals GmbH; 2024.
6. DYSPORT®. Prescribing Information. Ipsen Biopharmaceuticals Ltd; 2023.
7. JEUVEAU®. Prescribing Information. Evolus, Inc; 2020.
8. Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020;82(4):838-845.
9. RHA® Direction for Use. Nashville, TN: Revance Therapeutics, Inc, 2023.

©2025 REVANCE AESTHETICS.

DAXXIFY, REVANCE THERAPEUTICS, AND THE REVANCE LOGO ARE REGISTERED TRADEMARKS OF REVANCE THERAPEUTICS, INC. RHA® is a registered trademark of TEOXANE SA, manufactured in Switzerland. The RHA® Collection is exclusively distributed by Revance Aesthetics™. RHA Redensity™ IS A TRADEMARK OF TEOXANE SA. ALL OTHER TRADEMARKS ARE THE PROPERTY OF THEIR RESPECTIVE OWNERS.

RA-003703.3

From TIME. © 2023 TIME USA LLC. All rights reserved. Used under license.

2024 Shape® Skin Award logo ©2024 Meredith Operations Corporation, a Dotdash Meredith company. Used under license.